COVID-19 and Heart: From Clinical Features to Pharmacological Implications

J Clin Med. 2020 Jun 22;9(6):E1944. doi: 10.3390/jcm9061944.


A highly pathogenic human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been recently recognized in Wuhan, China, as the cause of the coronavirus disease 2019 (COVID-19) outbreak which has spread rapidly from China to other countries in the world, causing a pandemic with alarming morbidity and mortality. The emerging epidemiological data about COVID-19 patients suggest an association between cardiovascular diseases (CVD) and SARS-CoV-2 infection, in term of clinical features at hospital admission and prognosis for disease severity. The aim of our review is to describe the cardiological features of COVID-19 patients at admission, the acute cardiac presentation, the clinical outcome for patients with underlying CVD and the pharmacological implications for disease management.

Keywords: angiotensin-converting enzyme inhibitor; arrhythmias; cardiac biomarkers; cardiovascular diseases; coronavirus disease 2019 (COVID-19); myocardial injury.

Publication types

  • Review